For instance, we previously reported crosstalk between Hippo/YAP and epidermal growth factor receptor (EGFR)-mitogen-activated protein kinase (MAPK) signaling pathways in human NSCLC and found that YAP could promote erlotinib resistance in EGFR mutant NSCLC cells [43,44]. This evidence concerns the gene WNK2 and non-small cell lung carcinoma.